$820,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter

Wall Street analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce $820,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $400,000.00 and the highest is $1.24 million. Dynavax Technologies reported sales of $150,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 446.7%. The business is scheduled to issue its next earnings results on Monday, May 14th.

According to Zacks, analysts expect that Dynavax Technologies will report full year sales of $820,000.00 for the current financial year, with estimates ranging from $11.19 million to $19.09 million. For the next year, analysts expect that the company will post sales of $115.93 million per share, with estimates ranging from $115.41 million to $116.45 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.32). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.53 million. Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%.

Several research analysts have weighed in on the company. BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, March 27th. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. Royal Bank of Canada reiterated a “buy” rating and set a $25.00 price objective on shares of Dynavax Technologies in a research report on Friday, March 9th. Cowen restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research report on Wednesday, February 21st. Finally, JPMorgan Chase cut Dynavax Technologies from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $31.00 to $25.00 in a research report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Dynavax Technologies currently has a consensus rating of “Buy” and a consensus price target of $24.67.

In related news, insider David F. Novack sold 16,109 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $16.30, for a total value of $262,576.70. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David F. Novack sold 2,121 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $17.97, for a total value of $38,114.37. Following the completion of the transaction, the insider now owns 77,192 shares in the company, valued at approximately $1,387,140.24. The disclosure for this sale can be found here. Insiders sold 52,444 shares of company stock worth $865,906 in the last 90 days. 2.90% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of DVAX. Nationwide Fund Advisors increased its position in shares of Dynavax Technologies by 257.0% in the third quarter. Nationwide Fund Advisors now owns 101,247 shares of the biopharmaceutical company’s stock worth $2,177,000 after purchasing an additional 72,888 shares during the period. Rhumbline Advisers grew its position in Dynavax Technologies by 16.8% in the third quarter. Rhumbline Advisers now owns 70,673 shares of the biopharmaceutical company’s stock valued at $1,519,000 after acquiring an additional 10,170 shares during the last quarter. Bank of New York Mellon Corp grew its position in Dynavax Technologies by 43.4% in the third quarter. Bank of New York Mellon Corp now owns 359,650 shares of the biopharmaceutical company’s stock valued at $7,733,000 after acquiring an additional 108,788 shares during the last quarter. SG Americas Securities LLC bought a new position in Dynavax Technologies in the third quarter valued at about $287,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Dynavax Technologies by 474.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 5,880 shares during the last quarter. Institutional investors own 71.22% of the company’s stock.

DVAX stock traded down $0.85 during trading hours on Tuesday, hitting $18.55. 1,251,942 shares of the stock were exchanged, compared to its average volume of 1,650,187. The stock has a market capitalization of $1,144.18, a price-to-earnings ratio of -10.72 and a beta of 0.84. Dynavax Technologies has a 12 month low of $5.05 and a 12 month high of $24.45.

COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/820000-00-in-sales-expected-for-dynavax-technologies-co-dvax-this-quarter.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply